3-Fluoro-L-tyrosine is a medium supplement.

CADD522 is a small molecule that inhibits the DNA binding of RUNX2. It negatively regulated transcription of RUNX2 target genes such as matrix metalloproteinase-13, vascular endothelial growth factor and glucose transporter-1, but upregulated RUNX2 expression by increasing RUNX2 stability. CADD522 may represent a potential antitumor drug.

AI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 μM.

α-methyl-dl-aspartic acid is an inhibitor of argininosuccinate synthase.

WNK463 is a potant With-No-Lysine (WNK) kinase inhibitor with IC50s of 5/1/6/9 nM for WNK1/2/3/4.

PKG Drug G1 targets C42 of PKG Iα. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.

Ursocholic acid is a bile acid, used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response.

RMC-4550 is a potent, selective and allosteric inhibitor of SHP2 enzyme with IC50 value of 0.58 nM, without activity against the SHP2 catalytic domain up to a concentration of 10 µM.

BR-1 is a cell-permeable PRL-3 inhibitor with IC50 value of 900nM. It dephosphorylates Tyr783 on integrin β1 and modulates VEGF-mediated endothelial cell migration.

Exherin is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities and selectively and competitively binds to and blocks N-cadherin.